Bibliographies thématiques / Tyrosine Kinase Inhibitors (TKIs)

Sommaire

Articles de revues
Thèses
Livres
Chapitres de livres
Actes de conférences
Rapports d'organisations

Littérature scientifique sur le sujet « Tyrosine Kinase Inhibitors (TKIs) »

Auteur : Grafiati

Publié le 9 mars 2023

Mis à jour le 31 juillet 2025

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Tyrosine Kinase Inhibitors (TKIs) ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "Tyrosine Kinase Inhibitors (TKIs)"

Deininger, Michael. "Targeting Tyrosine Kinase Receptors." Blood 122, no. 21 (2013): SCI—25—SCI—25. http://dx.doi.org/10.1182/blood.v122.21.sci-25.sci-25.

Texte intégral

Résumé :

Abstract Protein tyrosine kinases (PTKs) regulate cell growth and other key functions. Constitutive PTK activation by somatic mutations, overexpression, or abnormal upstream signaling is characteristic of many cancers, including hematologic malignancies, providing a rationale for therapeutically targeting PTKs with small molecules. Imatinib, an ATP-competitive inhibitor of BCR-ABL1, the PTK causal to chronic myeloid leukemia (CML), established a paradigm for tyrosine kinase inhibitors (TKIs) as cancer therapeutics. Although a relatively weak inhibitor, imatinib is effective in most patients wi

Styles APA, Harvard, Vancouver, ISO, etc.

Abruzzese, Elisabetta, Malgorzata Monika Trawinska, Paolo De Fabritiis, and Alessio Pio Perrotti. "TYROSINE KINASE INHIBITORS AND PREGNANCY." Mediterranean Journal of Hematology and Infectious Diseases 6, no. 1 (2014): e2014028. http://dx.doi.org/10.4084/mjhid.2014.028.

Texte intégral

Résumé :

The management of patients with chronic myeloid leukemia (CML) during pregnancy has became recently a matter of continuous debate. The introduction of the Tyrosine Kinase Inhibitors (TKIs) in clinical practice has dramatically changed the prognosis of CML patients. Patients diagnosed in chronic phase can reasonably expect many years of excellent disease control and good quality of life, as well as a normal life expectancy. This fact has come the necessity to address issues relating to fertility and pregnancy. Physicians are not infrequently being asked for advice regarding the need for, and or

Styles APA, Harvard, Vancouver, ISO, etc.

Weatherald, Jason, Louise Bondeelle, Marie-Camille Chaumais, et al. "Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors." European Respiratory Journal 56, no. 4 (2020): 2000279. http://dx.doi.org/10.1183/13993003.00279-2020.

Texte intégral

Résumé :

Tyrosine kinase inhibitors (TKIs) targeting the Bcr-Abl oncoprotein revolutionised the treatment of chronic myelogenous leukaemia. Following the success of imatinib, second- and third-generation molecules were developed. Different profiles of kinase inhibition and off-target effects vary between TKIs, which leads to a broad spectrum of potential toxicities.Pulmonary complications are most frequently observed with dasatinib but all other Bcr-Abl TKIs have been implicated. Pleural effusions are the most frequent pulmonary complication of TKIs, usually associated with dasatinib and bosutinib. Pul

Styles APA, Harvard, Vancouver, ISO, etc.

Rajeswari, Aruna, and Balaprakash Bhavani. "The Role of Tyrosine Kinases in Cancer: Signal Transduction Mechanisms and Therapeutic Targets." International Journal of Health Sciences and Research 14, no. 9 (2024): 320–36. http://dx.doi.org/10.52403/ijhsr.20240942.

Texte intégral

Résumé :

Tyrosine kinases are key mediators in cellular signaling, governing essential processes such as growth, differentiation, metabolism, and apoptosis. In cancer, these kinases often become dysregulated due to mutations, overexpression, or autocrine-paracrine signaling, leading to uncontrolled cell proliferation and tumor development. Receptor tyrosine kinases (RTKs), a prominent subset, are frequently implicated in cancer, with many tumors exhibiting dependency on aberrant RTK signaling. This dependency has made RTKs a major focus for targeted cancer therapies, particularly through the developmen

Styles APA, Harvard, Vancouver, ISO, etc.

Hu, Chunqi, and Xiaowu Dong. "Cysteine-targeted Irreversible Inhibitors of Tyrosine Kinases and Key Interactions." Current Medicinal Chemistry 26, no. 31 (2019): 5811–24. http://dx.doi.org/10.2174/0929867325666180713124223.

Texte intégral

Résumé :

Tyrosine kinases are a subgroup of a large class of protein kinases that transfer phosphate groups from ATP to various amino acid residues. By phosphorylating the tyrosine residues, the tyrosine kinases are responsible for the activation of various proteins through signal transduction cascades, which serves as a ubiquitous mechanism of cell signaling. The frequent success of many tyrosine kinase inhibitors (TKIs) in clinical success and diseasecausing mutations in protein kinases suggests that a large number of kinases may represent therapeutically relevant targets. To date, most of the clinic

Styles APA, Harvard, Vancouver, ISO, etc.

Jacobs, Chaja F., Eric Eldering, and Arnon P. Kater. "Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19." Blood Advances 5, no. 3 (2021): 913–25. http://dx.doi.org/10.1182/bloodadvances.2020003768.

Texte intégral

Résumé :

Abstract Tyrosine kinase inhibitors (TKIs) are used to target dysregulated signaling pathways in virtually all hematologic malignancies. Many of the targeted signaling pathways are also essential in nonmalignant immune cells. The current coronavirus severe acute respiratory syndrome coronavirus 2 pandemic catalyzed clinical exploration of TKIs in the treatment of the various stages of COVID-19, which are characterized by distinct immune-related complications. Most of the reported effects of TKIs on immune regulation have been explored in vitro, with different class-specific drugs having nonove

Styles APA, Harvard, Vancouver, ISO, etc.

Moradpour, Zahra, and Leila Barghi. "Novel Approaches for Efficient Delivery of Tyrosine Kinase Inhibitors." Journal of Pharmacy & Pharmaceutical Sciences 22 (January 13, 2019): 37–48. http://dx.doi.org/10.18433/jpps29891.

Texte intégral

Résumé :

Epidermal growth factor receptors (EGFRs) have potential to be considered as therapeutic target for cancer treatment especially in cancer patients with overexpression of EGFR. Cetuximab as a first monoclonal antibody and Imatinib as the first small molecule tyrosine kinase inhibitor (SMTKI) were approved by FDA in 1998 and 2001. About 28 SMTKIs have been approved until 2015 and a large number of compound with kinase inhibitory activity are at the different phases of clinical trials. Although Kinase inhibitors target specific intracellular pathways, their tissue or cellular distribution are not

Styles APA, Harvard, Vancouver, ISO, etc.

Jabbar, Sarah, and Mohammed Mohammed. "An in silico study of new 1-aminoquinoline-2(1H)-one derivatives as tyrosine kinase inhibitors." Turkish Computational and Theoretical Chemistry 9, no. 1 (2024): 63–74. https://doi.org/10.33435/tcandtc.1500969.

Texte intégral

Résumé :

The field of oncology has been revolutionized by the discovery and development of targeted therapies for cancer. A study focuses on the development of tyrosine kinase inhibitors (TKIs) as effective targeted therapies. Although TKIs have shown promise in targeting cancer cell signaling pathways, the emergence of resistance poses a significant challenge, necessitating the development of novel and potent inhibitors. Virtual docking simulations, which use molecular docking algorithms and scoring functions, predict how these TKIs bind to the enzyme and assess their binding strength. Preliminary res

Styles APA, Harvard, Vancouver, ISO, etc.

Aldaz, Paula, and Imanol Arozarena. "Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?" Cancers 13, no. 22 (2021): 5799. http://dx.doi.org/10.3390/cancers13225799.

Texte intégral

Résumé :

Glioblastoma (GBM) is the most common and lethal form of malignant brain tumor. GBM patients normally undergo surgery plus adjuvant radiotherapy followed by chemotherapy. Numerous studies into the molecular events driving GBM highlight the central role played by the Epidermal Growth Factor Receptor (EGFR), as well as the Platelet-derived Growth Factor Receptors PDGFRA and PDGFRB in tumor initiation and progression. Despite strong preclinical evidence for the therapeutic potential of tyrosine kinase inhibitors (TKIs) that target EGFR, PDGFRs, and other tyrosine kinases, clinical trials performe

Styles APA, Harvard, Vancouver, ISO, etc.

Roy, Bhaskar, Avash Das, Kumar Ashish, et al. "Neuropathy with vascular endothelial growth factor receptor tyrosine kinase inhibitors." Neurology 93, no. 2 (2019): e143-e148. http://dx.doi.org/10.1212/wnl.0000000000007743.

Texte intégral

Résumé :

ObjectiveTo explore the association of peripheral neuropathy with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) use in patients with cancer.MethodsPublished data search up to November 2018 reporting peripheral neuropathy in patients with cancer treated with VEGFR-TKIs was performed. The primary outcome was presence of peripheral neuropathy at the end of the trial. Random-effects meta-analysis was performed to estimate relative risk (RR) of individual treatment.ResultsThirty randomized clinical trials (RCTs) including 12,490 patients with cancer were includ

Styles APA, Harvard, Vancouver, ISO, etc.

Plus de sources

Thèses sur le sujet "Tyrosine Kinase Inhibitors (TKIs)"

Recondo, Gonzalo. "Resistance Mechanisms to ALK Tyrosine Kinase Inhibitors (TKIs) in NSCLC." Thesis, Université Paris-Saclay (ComUE), 2019. http://www.theses.fr/2019SACLS248/document.

Texte intégral

Résumé :

Les analyses moléculaires et la classification des adénocarcinomes bronchiques ont conduit au développement de thérapies ciblées sélectives visant à améliorer le contrôle de la maladie et la survie des patients. ALK (anaplastic lymphoma kinase) est un récepteur tyrosine kinase de la famille des récepteurs de l'insuline. Des réarrangements chromosomiques impliquant le domaine kinase d’ALK sont présents dans environ 3 à 6% des patients atteints d'un adénocarcinome bronchique. La protéine de fusion provoque une activation du domaine kinase de manière constitutive et indépendante du ligand. Lorlat

Styles APA, Harvard, Vancouver, ISO, etc.

Grassi, Susanna. "BCR/ABL1-independent markers of resistance in patients affected by chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitors (TKIs)." Doctoral thesis, Università di Siena, 2019. http://hdl.handle.net/11365/1073133.

Texte intégral

Résumé :

Chronic Myeloid Leukemia (CML) is a chronic myeloproliferative neoplasm derived from the neoplastic transformation of the pluripotent stem cell characterized by the reciprocal translocation between chromosome 9 (9q) and 22 (22q) t (9; 22) (q34; q11), which leads to the formation of a new BCR-ABL1 gene that causes expansion of the pathological clone. The introduction of tyrosine kinase inhibitor drugs (TKIs) has revolutionized the treatment of this neoplasm. However, about a third of patients have to suspend treatment for resistance or intolerance to TKIs. The aim of our study was to identify t

Styles APA, Harvard, Vancouver, ISO, etc.

SARONNI, DAVIDE. "TYROSINE KINASE INHIBITORS IN NEUROENDOCRINE TUMORS: FROM IN VITRO TO ZEBRAFISH MODEL." Doctoral thesis, Università degli Studi di Milano, 2022. http://hdl.handle.net/2434/917967.

Texte intégral

Résumé :

(1) Background: Neuroendocrine neoplasms (NENs) are a group of tumors that arise from neuroendocrine cells throughout the body, with the lungs and gastrointestinal tract being the most common sites of origin. In patients with NENs and distant metastases, surgery is generally not curative. Although well-differentiated and low-grade NENs, classified as neuroendocrine tumors (NETs), are usually less aggressive than poorly-differentiated NENs, they can develop distant metastases in about 15% of cases. These patients require chronic medical management. However, the clinical efficacy of these treatm

Styles APA, Harvard, Vancouver, ISO, etc.

DAMELE, LAURA. "Effect of tyrosine kinase inhibitors on NK cell and ILC3 dvelopment and function." Doctoral thesis, Università degli studi di Genova, 2020. http://hdl.handle.net/11567/996010.

Texte intégral

Résumé :

Tyrosin kinase inhibitors (TKI) sharply improved the prognosis of Chronic Myeloid Leukemia (CML) and of Philadelphia+ Acute Lymphoblastic Leukemia (Ph+ALL) patients. However, TKI are not curative because of the development of resistance and lack of complete molecular remission in the majority of patients. Clinical evidences would support the notion that patient’s immune system may play a key role in preventing relapses. In particular, increased proportions of terminally differentiated CD56+CD16+CD57+ NK cells have been reported to be associated with successful Imatinib therapy discontin

Styles APA, Harvard, Vancouver, ISO, etc.

Kangboonruang, Kitsada. "Neoplastic mast cells from patients with mastocytosis express AXL : effects on proliferation, apoptosis, and resistance to tyrosine kinase inhibitors." Electronic Thesis or Diss., Université Paris Cité, 2024. https://wo.app.u-paris.fr/cgi-bin/WebObjects/TheseWeb.woa/wa/show?t=6722&f=79753.

Texte intégral

Résumé :

La mastocytose est une maladie rare et hétérogène, caractérisée par l'accumulation de mastocytes (MC) néoplasiques dans un ou plusieurs organes. L'Organisation Mondiale de la Santé (OMS) a classé la mastocytose en plusieurs variantes, dont la mastocytose cutanée (CM), limitée à la peau, la mastocytose systémique (MS), qui affecte la moelle osseuse et divers organes, ainsi que le sarcome mastocytaire (MCS), une tumeur localisée rare et agressive. La MS est ensuite subdivisée en MS non avancée (comprenant la MS indolente (ISM) et la MS à évolution lente (SSM)) et en MS avancées (AdvSM). L'AdvSM

Styles APA, Harvard, Vancouver, ISO, etc.

Aljohani, Hashim M. B. S. "Signaling Pathways Associated with Gefitinib Resistance in Glioblastoma Multiforme (GBM)." University of Cincinnati / OhioLINK, 2014. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1406900804.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Tonus, Francesca. "Sintesi e studio di sistemi polieterociclici a potenziale attività biologica." Doctoral thesis, Università degli studi di Padova, 2012. http://hdl.handle.net/11577/3425459.

Texte intégral

Résumé :

In the last decade, some progresses have been reached in the cancer treatment, mainly through the approval of novel key drugs based on the targeted therapy. In this respect, tyrosine kinases constitute one of the most relevant class of targets. Tyrosine kinases are key enzymes involved in the intracellular signal transduction and their up-regulation is often associated with cancer onset and progression. The tyrosine kinase inhibitors act mainly as ATP-mimic compounds. Despite the initial relevant clinical successes obtained through kinase inhibitor use, rapid drug resistance phenomena onset ha

Styles APA, Harvard, Vancouver, ISO, etc.

Russell, Kathy, Marion Slack, Janet Cooley, and Kelly Mathews. "Impact of a Specialty Pharmacy-Based Oral Chemotherapy Adherence Program on Patient Adherence." The University of Arizona, 2016. http://hdl.handle.net/10150/614015.

Texte intégral

Résumé :

Class of 2016 Abstract<br>Objectives: Patient medication adherence is a basic requirement for treating chronic myelogenous leukemia (CML) with oral tyrosine kinase inhibitors (TKIs). When imatinib adherence rates are less than 80 or 90 percent, major and complete molecular responses, respectively, do not happen. The purpose of this study was to determine the effect of a real-time medication monitoring (RTMM) reminder system adherence program on the medication possession ratio (MPR). Methods: This analytic study was a retrospective cohort study and used data extracted from chart reviews for pa

Styles APA, Harvard, Vancouver, ISO, etc.

Choi, Ho-ying, and 蔡可盈. "Review of clinical benefits and cost effectiveness of epidermal growthfactor receptor-tyrosine kinase inhibitor (EGFR-TKI) as first linetreatment for patients with advanced non-small cell lung cancer(NSCLC)." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2011. http://hub.hku.hk/bib/B46935320.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Mazed, Fetta. "Etude des mécanismes de résistance aux inhibiteurs de FLT3 dans les leucémies aigues myéloïdes." Thesis, Sorbonne Paris Cité, 2019. http://www.theses.fr/2019USPCC089.

Texte intégral

Résumé :

Les leucémies aiguës myéloïdes (LAM) constituent un groupe hétérogène d’hémopathies malignes résultant de la prolifération clonale d’un progéniteur myéloïde bloqué dans sa différenciation. De pronostic globalement défavorable, dépend de l’âge et de facteurs cytogénétiques et moléculaires. La mutation du gène FLT3 de type duplication en tandem du domaine juxta-membranaire (ITD : internal tandem duplication) est détectée dans 30% des échantillons de LAM, corrèle à une fréquence accrue de rechutes et à un pronostic défavorable. La mutation ITD conduit à une activation dérégulée et constitutive de

Styles APA, Harvard, Vancouver, ISO, etc.

Plus de sources

Livres sur le sujet "Tyrosine Kinase Inhibitors (TKIs)"

Focosi, Daniele, ed. Resistance to Tyrosine Kinase Inhibitors. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-46091-8.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

D, Fabbro, and McCormick Frank 1950-, eds. Protein tyrosine kinases: From inhibitors to useful drugs. Humana Press, 2006.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Rommel, Christian. Phosphoinositide 3-kinase in Health and Disease: Volume 2. Springer-Verlag Berlin Heidelberg, 2011.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Matthews, David J. Targeting protein kinases for cancer therapy. John Wiley & Sons, 2009.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Focosi, Daniele. Resistance to Tyrosine Kinase Inhibitors. Springer International Publishing AG, 2018.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Focosi, Daniele. Resistance to Tyrosine Kinase Inhibitors. Springer, 2016.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Focosi, Daniele. Resistance to Tyrosine Kinase Inhibitors. Springer, 2016.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

McCormick, Frank. Protein Tyrosine Kinases: From Inhibitors to Useful Drugs. Humana Press, 2005.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

McCormick, Frank, and Doriano Fabbro. Protein Tyrosine Kinases: From Inhibitors to Useful Drugs. Humana Press, 2010.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

(Editor), Doriano Fabbro, and Frank McCormick (Editor), eds. Protein Tyrosine Kinases: From Inhibitors to Useful Drugs (Cancer Drug Discovery and Development). Humana Press, 2005.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Plus de sources

Chapitres de livres sur le sujet "Tyrosine Kinase Inhibitors (TKIs)"

Kozan, Esin Oguz, and Eyup Naci Tiftik. "Immunotherapy in Chronic Leukemias." In Immunotherapy in Human Cancers. Nobel Tip Kitabevleri, 2024. http://dx.doi.org/10.69860/nobel.9786053359388.7.

Texte intégral

Résumé :

Chronic myelogenous leukemia (CML) is a clonal myeloproliferative hematopoietic stem cell disorder. The most important immunotherapeutic drugs in the treatment of CML are tyrosine kinase inhibitors (TKI) and interferon. Chronic lymphocytic leukemia, another type of chronic leukemia, is one of the B cell chronic lymphoproliferative disorders. It is used in the treatment of three types of drug groups: anti-CD20 monoclonal antibodies, anti-CD19 monoclonal antibodies and bruton thyrosine kinase inhibitors.

Styles APA, Harvard, Vancouver, ISO, etc.

Finessi, M., V. Liberini, and D. Deandreis. "Definition of Radioactive Iodine Refractory Thyroid Cancer and Redifferentiation Strategies." In Integrated Diagnostics and Theranostics of Thyroid Diseases. Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-35213-3_9.

Texte intégral

Résumé :

AbstractDifferentiated Thyroid Cancer (DTC) presents a 10-year survival rate of > 90% in case of localized disease while in case of distant metastases prognosis is poorer. Radioactive iodine is the first-line therapy for ablation, adjuvant intent, and for the treatment of distant metastases.In case of distant metastases, 50% of these patients obtain complete remission or stabilization of the disease over a long-term period with RAI therapy. Unfortunately, the remaining 50% of these patients, with the most aggressive and rapidly progressive disease, develop a RAI refractory disease thyroid c

Styles APA, Harvard, Vancouver, ISO, etc.

Cakar, Burcu, and Erdem Göker. "Tyrosine Kinase Inhibitors." In Breast Disease. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-26012-9_36.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Cakar, Burcu, and Erdem Göker. "Tyrosine Kinase Inhibitors." In Breast Disease. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16792-9_35.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Duhé, Roy J. "Tyrosine Kinase Inhibitors." In Encyclopedia of Cancer. Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-27841-9_6080-2.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Abad, Cybele Lara R., and Raymund R. Razonable. "Tyrosine-Kinase Inhibitors." In Infectious Complications in Biologic and Targeted Therapies. Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-11363-5_15.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Duhé, Roy J. "Tyrosine Kinase Inhibitors." In Encyclopedia of Cancer. Springer Berlin Heidelberg, 2017. http://dx.doi.org/10.1007/978-3-662-46875-3_6080.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Duhé, Roy J. "Tyrosine Kinase Inhibitors." In Encyclopedia of Cancer. Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-16483-5_6080.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Champagne, Trevor. "Tyrosine-Kinase Inhibitors." In Litt's Drug Eruption & Reaction Manual, 31st ed. CRC Press, 2025. https://doi.org/10.1201/9781003569756-1524.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Latham, Antony M., Jayakanth Kankanala, and Sreenivasan Ponnambalam. "Receptor Tyrosine Kinase Inhibitors." In Encyclopedia of Cancer. Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-27841-9_7196-1.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Actes de conférences sur le sujet "Tyrosine Kinase Inhibitors (TKIs)"

Yalcin, Huseyin, Hissa Al-Thani, and Samar Shurbaji. "Development and In Vivo Testing of Smart Nanoparticles for Enhanced Anti-Cancer Activity and Reduced Cardiotoxicity Associated with Tyrosine Kinase Inhibitors." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2021. http://dx.doi.org/10.29117/quarfe.2021.0088.

Texte intégral

Résumé :

Tyrosine kinase inhibitors (TKIs) are new generation of anti-cancer drugs with very high efficiency against cancer cells. However, TKIs are associated with severe cardiotoxicity limiting their clinical benefits. One TKI that has been developed recently but not explored much is Ponatinib. The use of nanoparticles as a better therapeutic agent to deliver anti-cancer drugs and reduce their cardiotoxicity has been recently considered. In this study, PLGA-PEG-PLGA nanoparticles were synthesized to deliver Ponatinib while reducing its cardiotoxicity for treatment of chronic myeloid leukemia. Shape,

Styles APA, Harvard, Vancouver, ISO, etc.

Kapoor, Gurpreet Singh, Yi Zhan, Heather Fetting, and Donald M. O'Rourke. "Abstract LB-11: PTEN modulates EGFRvIII-induced SHP2 phosphorylation and translocation to affect glioblastoma sensitivity to tyrosine kinase inhibitors (TKIs)." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-lb-11.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Honeywell, Richard J., Sarina Hitzerd, Ietje Kathmann, Elisa Giovannetti, Henk Verheul, and Frits Peters. "Abstract 4425: Characterisation of cellular transport and accumulation of six clinically approved tyrosine kinase inhibitors (TKIs) in colon cancer cells." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-4425.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Cascone, Tina, Matthew H. Herynk, Li Xu, et al. "Abstract 376: Increased HGF is associated with resistance to VEGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC)." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-376.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Zhao, Jane, Adriana Guerrero, Kevin Kelnar, Heidi J. Peltier, and Andreas G. Bader. "Abstract 4814: miRNA combination therapy:In vitroanticancer synergy between miR-34a mimic and next generation EGFR tyrosine kinase inhibitors (TKIs) in NSCLC." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-4814.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Ward, Richard A., Ambra Bianco, Nicola Colclough, et al. "Abstract 4813: Comparative activity profiling of tyrosine kinase inhibitors (TKIs) against exon 20 insertions and the wild-type form of epidermal growth factor receptor (EGFR)." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-4813.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Papayannidis, Cristina, Ilaria Iacobucci, Simona Soverini, et al. "Abstract 1804: Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-1804.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Lee, N., JL Lee, and JY Lee. "5PSQ-005 Analysis of anti-angiogenesis-related adverse events associated with vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) in patients with metastatic renal cell carcinoma." In 27th EAHP Congress, Lisbon, Portugal, 22-23-24 March 2023. British Medical Journal Publishing Group, 2023. http://dx.doi.org/10.1136/ejhpharm-2023-eahp.233.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Fan, Ni, Yiyu Zou, Balazs Halmos, Roman Perez-Soler, and Haiying Cheng. "Abstract 4748: RICTOR signaling modulates the activity of EGFR tyrosine kinase inhibitors (TKI) inEGFR-mutated non-small cell lung cancer (NSCLC)." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-4748.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Rapports d'organisations sur le sujet "Tyrosine Kinase Inhibitors (TKIs)"

Song, Yaowen, Shuiyu Lin, Jun Chen, Silu Ding, and Jun Dang. First-line treatment with TKI plus brain radiotherapy vs TKI alone in EGFR-mutated non-small-cell lung cancer with brain metastases: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.1.0013.

Texte intégral

Résumé :

Review question / Objective: It remains uncertain whether first-line treatment with upfront brain radiotherapy (RT) in combination with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is superior to EGFR-TKIs alone in EGFR-mutated non-small-cell lung cancer with newly diagnosed brain metastases (BMs). We performed a meta-analysis to address this issue. Condition being studied: Brain radiotherapy (RT) has been shown to damage the blood-brain barrier (BBB) and improve the concentration of EGFR-TKIs in the CSF. Additionally, RT can result in a reduction of EGFR-TKIs resist

Styles APA, Harvard, Vancouver, ISO, etc.

Miller, Tod. Peptide-Bassed Inhibitors of Neu Tyrosine Kinase. Defense Technical Information Center, 1999. http://dx.doi.org/10.21236/ada375133.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Miller, W. T. Peptide-Based Inhibitors of Neu Tyrosine Kinase. Defense Technical Information Center, 2000. http://dx.doi.org/10.21236/ada392289.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Rosen, Neal. Development of Targeted Ansamycins as Novel Antiestrogens and Tyrosine Kinase Inhibitors. Defense Technical Information Center, 1998. http://dx.doi.org/10.21236/ada369205.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Rosen, Neal. Development of Targeted Ansamycins as Noval Antiestrogens and Tyrosine Kinase Inhibitors. Defense Technical Information Center, 2000. http://dx.doi.org/10.21236/ada413599.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Tinker, Anna V., Neesha C. Dhani, Prafull Ghatage, et al. Immune Checkpoint Inhibitors in Pretreated Metastatic Endometrial Cancer. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.1.0038.

Texte intégral

Résumé :

Review question / Objective: Efficacy and safety of immune checkpoint inhibitors alone or in combination with tyrosine kinase inhibitors in patients with pretreated advanced, persistent, or recurrent metastatic endometrial cancer. Condition being studied: Advanced, persistent, or recurrent metastatic endometrial cancer. Study designs to be included: Non-randomized studies of monotherapy in populations selected for relevant biomarkers such as MMR, microsatellite stability, and PD-L1 expression status and randomized trials of ICI combinations in unselected patients.

Styles APA, Harvard, Vancouver, ISO, etc.

Chen, Yueying, Yanjun Du, Dong Wang, Ping Zhan, Hedong Han, and Tangfeng Lv. New Options for Advanced NSCLC Patients Resistant to EGFR Tyrosine Kinase Inhibitors – A Systematic Review and Network Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2025. https://doi.org/10.37766/inplasy2025.1.0014.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Wang, Zexian, Yaru Guo, Xiaojin Wu, Xiaohan Qin, Zhiling Wan, and Chen Liu. Bevacizumab plus Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor versus EGFR-TKI alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.12.0059.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Qin, Xiaohan, Yaru Guo, Xiaojin Wu, Zexian Wang, Zhiling Wan, and Chen Liu. Chemotherapy plus Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor versus EGFR-TKI alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2024. http://dx.doi.org/10.37766/inplasy2024.1.0128.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Liu, Xionglin, Jindu Li, Minjun Li, and Bangde Xiang. Efficacy and Safety of Tyrosine Kinase Inhibitors in Advanced Hepatocellular Carcinoma Patients with Child-Pugh A and B Cirrhosis: A Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2024. http://dx.doi.org/10.37766/inplasy2024.10.0130.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!